Cuál es la capitalización de mercado por Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Capitalización de mercado por Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) es $5.17B

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) EPS

Q: Cuál es el precio por Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Precio por Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) es de$4.64

Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.

Año	EPS	Cambiar
Not enough data for the provided dates.

Año

EPS

Cambiar

Not enough data for the provided dates.

Empresa	EPS	Diferencia de EPS	País
Intuitive Surgical, Inc. ISRG.US	$8.85	-	US
EssilorLuxottica S.A. EL.PA	$6.41	-	FR
HOYA Corporation 7741.T	-	-	JP
Becton, Dickinson and Company BDX.US	$3.32	-	US
Alcon Inc. ALC.SW	-	-	CH

Empresa

EPS

Diferencia de EPS

País